A novel small-molecule enantiomeric analogue of traditional (−)-morphinans has specific TLR9 antagonist properties and reduces sterile inflammation-induced organ damage
Publication
, Journal Article
Farooq, A
Published in: The Journal of immunology
April 4, 2014
Duke Scholars
Published In
The Journal of immunology
Publication Date
April 4, 2014
Volume
190
Issue
8
Start / End Page
4297 / 4304
Related Subject Headings
- Immunology
- 1107 Immunology
Citation
APA
Chicago
ICMJE
MLA
NLM
Farooq, A. (2014). A novel small-molecule enantiomeric analogue of traditional (−)-morphinans has specific TLR9 antagonist properties and reduces sterile inflammation-induced organ damage. The Journal of Immunology, 190(8), 4297–4304.
Farooq, A. “A novel small-molecule enantiomeric analogue of traditional (−)-morphinans has specific TLR9 antagonist properties and reduces sterile inflammation-induced organ damage.” The Journal of Immunology 190, no. 8 (April 4, 2014): 4297–4304.
Farooq A. A novel small-molecule enantiomeric analogue of traditional (−)-morphinans has specific TLR9 antagonist properties and reduces sterile inflammation-induced organ damage. The Journal of immunology. 2014 Apr 4;190(8):4297–304.
Farooq, A. “A novel small-molecule enantiomeric analogue of traditional (−)-morphinans has specific TLR9 antagonist properties and reduces sterile inflammation-induced organ damage.” The Journal of Immunology, vol. 190, no. 8, Apr. 2014, pp. 4297–304.
Farooq A. A novel small-molecule enantiomeric analogue of traditional (−)-morphinans has specific TLR9 antagonist properties and reduces sterile inflammation-induced organ damage. The Journal of immunology. 2014 Apr 4;190(8):4297–4304.
Published In
The Journal of immunology
Publication Date
April 4, 2014
Volume
190
Issue
8
Start / End Page
4297 / 4304
Related Subject Headings
- Immunology
- 1107 Immunology